Perspective Therapeutics has announced the first patient was treated with [212Pb]PSV359 in a Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical [212Pb]PSV359 in patients with solid tumors that express fibroblast activation protein alpha (FAP-α).

Strategic partnership between IDT and Elegen marks launch of early access program offering rapid, long, clonal gene synthesis and high-complexity genes up to 15 kb

Dr. Mark Greiner and his research team, based at the Iowa Lions Eye Bank within the BioVentures Center, are using a five-year, $2.85 million grant from the National Eye Institute to develop a topical drug therapy designed to prevent vision loss caused by Fuchs endothelial corneal dystrophy.

While the world experiences volatility, our mission remains unchanged: to produce renewable hydrogen for the world at an economical price.

Perspective Therapeutics has announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) taking place January 23-25, 2025 in San Francisco, CA.

The Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa was awarded a grant of just over $1 million through the Strategic Infrastructure Grant program to expand the existing biomanufacturing infrastructure in the state.

Integrated DNA Technologies (IDT) has appointed Ajay Gannerkote as president.

Perspective Therapeutics, Inc. has announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025.